Prediction of HIV peptide epitopes by a novel algorithm

AIDS Research and Human Retroviruses

Volumn 12, Issue 7, 1996, Pages 593-610

  Roberts, Caroline G P ^a   Meister, Gabriel E ^a   Jesdale, Bill M ^a   Lieberman, Judy ^b   Berzofsky, Jay A ^c   De Groot, Anne S ^a,d,e  

^a BROWN UNIVERSITY   (United States)

^b CENTER FOR BLOOD RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MIRIAM HOSPITAL   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEF PROTEIN;

ALGORITHM; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION;

EID: 0029985221     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.593     Document Type: Article

References (88)

1. Habeshaw JA, Dalgleish AG, Bountiff L, Newell AL, Wilks D, Walker LC, and Manca F: AIDS pathogenesis: HIV envelope and its interaction with cell proteins. Immunol Today 1990;11:418-425.
2. Miller SB, Tse H, Rosenspire AJ, and King SR: CD4-independent inhibition of lymphocyte proliferation mediated by HIV-1 envelope glycoproteins. Virology 1992;191:973-977.
3. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, and Moudgil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993;11:729-766.
4. Hosmalin A, Clerici M, Houghten R, Pendleton CD, Flexner C, Lucey DR, Moss B, Germain RN, Shearer GM, and Berzofsky JA: An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1990;87:2344-2348.
5. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R, Moss B, and Schooley RT: Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989;86:9514-9518.
6. De Groot AS, Clerici M, Hosmalin A, Hughes SH, Barnd D, Hendrix CW, Houghten R, Shearer GM, and Berzofsky JA: Human immunodeficiency virus reverse transcriptase T helper epitopes identified in mice and humans: correlation with a cytotoxic T cell epitope. J Infect Dis 1991;164:1058-1065.
7. Haas G, David R, Frank R, Gausepohl H, Devaux C, Claverie JM, and Pierres M: Identification of a major human immunodeficiency virus-1 reverse transcriptase epitope recognized by mouse CD4+ T lymphocytes. Eur J Immunol 1991;21:1371-1377.
8. Lieberman J, Fabry JA, Kuo MC, Earl P, Moss B, and Skolnik PR: Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in gp160 and reverse transcriptase. J Immunol 1992;148:2738-2747.
9. Hosmalin A, Kumar S, Barnd D, Houghten R, Smith GE, Hughes SH, and Berzofsky JA: Immunization with soluble protein-pulsed spleen cells induces class I-restricted cytotoxic T lymphocytes that recognize immunodominant epitopic peptides from Plasmodium falciparum and HIV-1. J Immunol 1992;149:1311-1318.
10. Blazevic V, Ranki A, Mattinen S, Valle SL, Koskimies S, Jung G, and Krohn KJ: Helper T-cell recognition of HIV-1 Tat synthetic peptides. J Acquir Immune Syndr 1993;6:881-890.
11. Michel F, Hoffenbach A, Froussand P, Langlade-Demoyen P, Kaczorek M, Kiény MP, and Plata F: HIV-1 env, nef and gag-specific T-cell immunity in mice: Conserved epitopes in nef p27 and gag p25 proteins. AIDS Res Hum Retroviruses 1992;8:469-478.
12. Bourgault I, Venet A, and Levy JP: Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes. J Virol 1992;66:750-756.
13. Graziano RF and Allen PM: Enhancing the immunogenicity of a permissive binding T cell epitope derived from the simian immunodeficiency virus-encoded negative regulatory factor. J Immunol 1992;149:556-561.
14. Estaquier J, Boutillon C, Ameisen JC, Gras-Masse H, Lecocq JP, Barbier B, Dixson A, Tartar A, Capron A, and Auriault C: T helper cell epitopes of the human immunodeficiency virus (HIV-1) nef protein in rats and chimpanzees. Mol Immunol 1992;29:489-499.
15. Culmann B, Gomard E, Kiény MP, Guy B, Dreyfus F, Saimot AG, Sereni D, and Levy JP: An antigenic peptide of the HIV-1 nef protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules. Eur J Immunol 1989;19:2383-2386.
16. Culmann B, Gomard E, Kiény MP, Guy B, Dreyfus F, Saimot AG, Sereni D, Sicard D, and Lévy JP: Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein. J Immunol 1991;146:1560-1565.
17. Koenig S, Fuerst TR, Wood LV, Woods RM, Suzich JA, Jones GM, de la Cruz VF, Davey RT Jr, Venkatesan S, Moss B, Biddison WE, and Fauci AS: Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. J Immunol 1990;145:127-135.
18. Hadida F, Parrot A, Kieny MP, Sadat-Sowti B, Mayaud C, Debre P, and Autran B: Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs: An in vitro limiting dilution analysis. J Clin Invest 1992;89:53-60.
19. Bahraoui E, Yagello M, Billaud JN, Sabatier JM, Muchmore E, Girard M, and Gluckman JC: Immunogenicity of the human immunodeficiency virus (HIV) recombinant nef gene product. Mapping of T-cell and B-cell epitopes in immunized chimpanzees. AIDS Res Hum Retroviruses 1990;6:1087-1098.
20. Wahren B, Rosen J, Sandström E, Mathiesen T, Modrow S, and Wigzell H: HIV-1 peptides induce a proliferate response in lymphocytes from infected persons. J Acquir Immune Defic Syndr 1989;2:448-456.
21. Schrier RD, Gnann JW Jr, Landes R, Lockshin CL, Richamn D, McCutchan A, Kennedy C, Oldstone MB, and Nelson JA: T cell recognition of HIV synthetic peptides in a natural infection. J Immunol 1989;142:1166-1176.
22. Shen L, Chen ZW, Miller MD, Stallard V, Mazzara GP, Panicali DL, and Letvin NL: Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science 1991;252:440-443.
23. Littaua RA, Oldstone MB, Takeda A, Debouck C, Wong JT, Tuazon CU, Moss B, Kievits F, and Ennis FA: An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag. J Virol 1991;65:4051-4056.
24. Littaua RA, Oldstone MB, Takeda A, and Ennis FA: A CD4+ cytotoxic T-lymphocyte clone to a conserved epitope on human immunodeficiency virus type 1 p24: Cytotoxic activity and secretion of interleukin-2 and interleukin-6. J Virol 1992;66:608-611.
25. van Baalen CA, Klein MR, Geretti AM, Keet RI, Miedema F, van Els CA, and Osterhaus AD: Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: Cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS 1993;7:781-786.
26. Yamamoto H, Miller MD, Tsubota H, Watkins DI, Mazzara GP, Stallard V, Panicali DL, Aldovini A, Young RA, and Letvin NL: Studies of cloned simian immunodeficiency virus-specific T lymphocytes. Gag-specific T lymphocytes exhibit a restricted epitope specificity. J Immunol 1990;144:3385-3391.
27. Mills KH, Barnard AL, Williams M, Page M, Ling C, Stott EJ, Silvera P, Taffs F, Kingsman AS, Adams SE, Almond N, Kitchin P, and Jones WC: Vaccine-induced CD4+ T cells against the simian immunodeficiency virus gag protein: Epitope specificity and relevance to protective immunity. J Immunol 1991;147:3560-3567.
28. Gotch F, McAdam SN, Allsopp CE, Gallimore A, Elvin J, Kieny MP, Hill AV, McMichael AJ, and Whittle HC: Cytotoxic T cells in HIV2 seropositive Gambians: Identification of a virus-specific MHC-restricted peptide epitope. J Immunol 1993;151:3361-3369.
29. Mills KH, Kitchin PA, Mahon BP, Barnard AL, Adams SE, Kingsman SM, and Kingsman AJ: HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1. J Immunol 1990;144:1677-1683.
30. Lehner T, Brookes R, Panagiotidi C, Tao C, Klavinskis LS, Walker J, Walker P, Ward R, Hussain L, Gearing JH, Adams S, and Bermeier LA: T- and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route. Proc Natl Acad Sci USA 1993;90:8638-8642.
31. Chong P, Sia C, Tam E, Kandil A, and Klein M: Synthesis and immunological characterization of a 134-mer synthetic peptide corresponding to the N-terminal half of the HIV-1 nucleoprotein, p24. Int J Peptide Protein Res 1993;41:21-27.
32. Buseyne F, McChesney M, Porrot F, Kovarik S, Guy B, and Riviere Y: Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24 gag protein. J Virol 1993;67:694-702.
33. Chong P, Sia C, Sydor M, and Klein M: Identification of a potent synthetic HIV1 immunogen compromising gag-p24 tandem T- and B-cell epitopes. FEBS Lett 1990;264:231-234.
34. Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, Buchanan TM, and Walker BD: HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 1991;147:1512-1521.
35. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallwey J, and McMichael AJ: HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature (London) 1988;336:484-487.
36. Nixon DF, Huet S, Rothbard J, Kieny MP, Delchambre M, Thiriart C, Rizza CR, Gotch FM, and McMichael AJ: An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. AIDS 1990;4:841-845.
37. Claverie J-M, Kourilsky P, Langlade-Demoyen P, Chalfour-Prochnicka A, Dadglio G, Tekaia F, Plata F, and Bougueleret L: T-immunogenic peptides are constituted of rare sequence patterns. Use in the identification of T epitopes in the human immunodeficiency virus gag protein. Eur J Immunol 1988;18:1547-1553.
38. Nixon DF and McMichael AJ: Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS 1991;5:1049-1059.
39. Gotch FM, Nixon DF, Alp N, McMichael AJ, and Borysiewicz LK: High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol 1990;2:707-712.
40. Miller MD, Yamamoto H, Hughes AL, Watkins DI, and Letvin NL: Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J Immunol 1991;147:320-329.
41. Earl PL, Koenig S, and Moss B: Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: Analysis of proteins with truncations and deletions expressed by recombinant vaccinia virus. J Virol 1991;65:31-41.
42. Lieberman J, Fabry JA, Kuo M-C, Earl P, Moss B, and Skolnik PR: Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. J Immunol 1992;148:2738-2747.
43. Hammond SA, Obah E, Stanhope P, Monell CR, Strand M, Robbins FM, Bias WB, Karr RW, Koenig S, and Siliciano RF: Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J Immunol 1991;146:1470-1477.
44. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL, DeLisi C, Moss B, Germain RN, and Berzofsky JA: An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988;85:8638-8642.
45. Berzofsky JA, Bensussan A, Cease KB, Bourge JF, Cheynier R, Lurhuma Z, Salaün JJ, Gallo RC, Shearer GM, and Zagury D: Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature (London) 1988;334:706-708.
46. Hale PM, Cease KB, Houghten RA, Ouyang C, Putney S, Javaherian K, Margalit H, Cornette JL, Spouge JL, DeLisi C, and Berzofsky JA: T cell multideterminant regions in the human immunodeficiency virus envelope: Toward overcoming the problem of major histocompatibility complex restriction. Int Immunol 1989;1:409-415.
47. Clerici M, Stocks NI, Zajac RA, Boswell RN, Bernstein DC, Mann DL, Shearer GM, and Berzofsky JA: Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature (London) 1989;339:383-385.
48. Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C, and Berzofsky JA: Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 1987;84:4249-4253.
49. Schrier RD, Gnann JW Jr, Landes R, Lockshin C, Richamn D, McCutchan A, Kennedy C, Oldstone MB, and Nelson JA: T cell recognition of HIV synthetic peptides in a natural infection. J Immunol 1989;142:1166-1176.
50. Ahearne PM, Matthews TJ, Lyerly HK, White GC, Bolognesi DP, and Weinhold KJ: Cellular immune responses to viral peptides in patients exposed to HIV. AIDS Res Hum Retroviruses 1988;4:259-267.
51. Takahashi K, Dai LC, Fuerst TR, Biddison WE, Earl PL, Moss B, and Ennis FA: Specific lysis of human immunodeficiency virus type 1-infected cells by an HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein. Proc Natl Acad Sci USA 1991;88:10277-10281.
52. Shirai M, Pendleton CD, and Berzofsky JA: Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. J Immunol 1992;148:1657-1667.
53. Johnson RP, Trocha A, Buchanan TM, and Walker BD: Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: Definition of minimum epitopes and analysis of the effects of sequence variation. J Exp Med 1992;175:961-971.
54. Achour A, Picard O, Mbika JP, Willer A, Snart R, Bizzini B, Carelli C, Burny A, and Zagury D: Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope. Vaccine 1993;11:699-701.
55. Clerici M, Lucey DR, Zajac RA, Boswell RN, Gebel HM, Takahashi H, Berzofsky JA, and Shearer GM: Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol 1991;146:2214-2219.
56. Dadaglio G, Leroux A, Langlade-Demoyen P, Bahraoui EM, Traincard F, Fisher R, and Plate F: Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes. J Immunol 1991;147:2302-2309.
57. Berzofsky JA, Pendleton CD, Clerici M, Ahlers J, Lucey DR, Putney SD, and Shearer GM: Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest 1991;88:876-884.
58. Clerici M, Tacket CO, Via CS, Lucey DR, Muluk SC, Zajac RA, Boswell RN, Berzofsy JA, and Shearer GM: Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur J Immunol 1991;21:1345-1349.
59. Margalit H, Spouge JL, Cornette JL, Cease KB, DeLisi C, and Berzofsky JA: Prediction of immunodominant helper T cell antigenic sites from the primary sequence. J Immunol 1987;138: 2213-2229.
60. Cornette JL, Margalit H, DeLisi C, and Berzofsky JA: The amphipathic helix as a structural feature involved in T cell recognition. In: The Amphipathic Helix. RM Epand (Ed). CRC Press, Boca Raton, FL, 1993.
61. Cornette JL, Margalit H, Berzofsky JA, and DeLisi C: Periodic variation in side chain polarities of T cell antigenic peptides correlates with their structure and activity. Proc Natl Acad Sci USA 1995;92:8368-8372.
62. Rötzschke O and Falk K: Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway. Immunol Today 1991;12:447-455.
63. Pamer EG, Harty JT, and Bevan MJ: Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature (London) 1991;353:852-855.
64. Calin-Laurens V, Trescol-Biémont M-C, Gerlier D, and Rabourdin-Combe C: Can one predict antigenic peptides for MHC class I-restricted cytotoxic T lymphocytes useful for vaccination? Vaccine 1993;11:974-978.
65. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch FM, Gao XM, Takiguchi M, Greenwood BM, Townsend AR, et al.: Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature (London) 1992;360:434-439.
66. Suhrbier A, Schmidt C, and Fernan A: Prediction of an HLA B8-restricted influenza epitope by motif. Immunology 1993;79:171-173.
67. Lipford GB, Hoffman M, Wagner H, and Heeg K: Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol 1993;150:1212-1222.
68. Sette A, Buus S, Appella E, Smith JA, Chesnut R, Miles C, Colon SM, and Gery HM: Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci USA 1989;86:3296-3300.
69. DiBrino M, Tsuchida T, Turner RV, Parker KC, Coligan JE, and Biddison WE: HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J Immunol 1993;151:5390-5395.
70. Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, Takacs B, and Sinigaglia F: Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1993;74:197-203.
71. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, and Lanzavecchia A: Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989;19:2237-2242.
72. Sette A, Sidney J, Albertson M, Miles C, Colon SM, Pedrazzini T, Lamont AG, and Grey HM: A novel approach to the generation of high affinity class II-binding peptides. J Immunol 1990;145: 1809-1813.
73. Meister GE, Roberts CGP, Berzofsky JA, and De Groot AS: Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 1995;13:581-591.
74. Dai LC, West K, Littaua R, Takahashi K, and Ennis FA: Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes. J Virol 1992;66:3151-3154.
75. Takahashi H, Merli S, Putney SD, Houghten R, Moss B, Germain RN, and Berzofsky JA: A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. Science 1989;246: 118-121.
76. Ranki A, Mattinen S, Yarchoan R, Broder S, Ghrayeb J, Lähdevirta J, and Krohn K: T-cell response toward HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS 1989;3:63-69.
77. Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, Ho HN, Nishanian PG, Berzofsky JA, and Shearer GM: Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992;165:1012-1019.
78. Carmichael A, Jin X, Sissons P, and Borysiewicz L: Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-256.
79. Hoffenbach A, Langlade-Demoyen P, Dadaglio G, Vilmer E, Michel H, Mayaud C, Autran B, and Plata F: Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 1989;142:452-462.
80. O'Toole C, Lowdell MW, Chargelegue D, and Colvin BT: Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study. AIDS Res Hum Retroviruses 1992;8:1361-1368.
81. Lieberman J, Fabray JA, Kuo M-C, Beckett L, and Skolnik PR: Ex vivo expansion of HIV-1 specific cytolytic T cells from HIV-1 seropositive subjects. AIDS Res Hum Retroviruses 1995;11: 257-271.
82. Ho PC, Mutch DA, Winkel KD, Saul AJ, Jones GL, Doran TJ, and Rzepczyk CM: Identification of two promiscuous T cell epitopes from tetanus toxin. Eur J Immunol 1990;20:477-483.
83. Greenstein JL, Schad VC, Goodwin WH, Brauer AB, Bollinger BK, Chin RD, and Kuo MCA: A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120. J Immunol 1992;148:3970-3977.
84. Sinigaglia F, Guttinger M, Kilgus J, Doran DM, Matile H, Etlinger H, Trzeciak A, Gillessen D, and Pink JR: A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature (London) 1988;336:778-780.
85. Kast WM, Brandt RMP, Drijhout JW, and Melief CJM: Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 1993;14:115-120.
86. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, and Sette A: Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-937.
87. De Groot AS, Carter EJ, Roberts CGP, Edelson BT, Jesdale BM, Meister GE, Houghten RA, Montoya J, Romulo RC, Berzofsky JA, and Ramirez BDLL: A novel algorithm for the efficient identification of T cell epitopes: prediction and testing of candidate TB vaccine peptides in genetically diverse populations. In: Vaccines 96. F Brown and E Norrby (Eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1996.
88. Gulukota K and DeLisi C: HLA allele selection for designing peptide vaccines. (Submitted).